The best pharmaceutical stocks right now include Eli Lilly, Johnson & Johnson, AbbVie, Merck, AstraZeneca, Pfizer, and Bristol Myers Squibb, chosen for their blockbuster drugs, growing pipelines, and financial strength. The industry is heading into one of the largest patent cliffs in its history. A patent cliff is the point when a drug loses its patent protection and faces cheaper copies, and medicines worth more than $200 billion in yearly sales could reach that point by 2030.
For investors, the question is which companies have new drugs ready to replace the old ones. The winners hold approved medicines that are still growing and pipelines deep enough to survive the losses ahead.
We screened the largest US-listed drugmakers and narrowed the field to seven based on approved products, revenue growth, and balance sheet strength.
How We Picked These Stocks
Dozens of pharmaceutical companies trade on US exchanges. We filtered for a market cap above $100 billion, at least one blockbuster drug already on the market, and a set of new treatments in late-stage testing. We looked for revenue growth, healthy operating margins (the share of sales left after the cost of running the business), and strong free cash flow (the cash left after bills and investments are paid). We left out smaller biotech companies that depend on a single experimental drug. The result is seven companies that span diabetes, cancer, immunology, and vaccines.
Eli Lilly (NYSE: LLY)
Why it made the list: Eli Lilly is the most valuable drug company in the world, and the reason is weight loss. Its diabetes and obesity treatments Mounjaro and Zepbound have become two of the fastest-selling medicines ever launched.
The bull case: Lilly now sells an obesity pill that is easier to take than the injections that built the market, and all three of the largest US pharmacy benefit managers cover its obesity drugs. Demand has been running ahead of supply for more than a year.
The risk: The stock trades at a high valuation, so any slowdown in obesity sales or a strong competing pill could pull it down sharply.
Key number: Eli Lilly is worth more than $1 trillion, the most of any pharmaceutical company on earth.
Johnson & Johnson (NYSE: JNJ)
Why it made the list: Johnson & Johnson is the most diversified name on this list, with a drug business and a medical device business under one roof. It sells more than two dozen products that each bring in over $1 billion a year.
The bull case: J&J has moved past its talc legal worries and is leaning on newer cancer and immunology drugs. It raised its dividend again this year, extending a streak that now tops six decades.
The risk: Its top immunology drug Stelara faces cheaper copies, called biosimilars, that will keep eating into sales over the next few years.
Key number: Johnson & Johnson has raised its dividend for more than 60 straight years, one of the longest streaks in the market.
AbbVie (NYSE: ABBV)
Why it made the list: AbbVie pulled off one of the hardest transitions in pharma. Its mega-blockbuster Humira lost patent protection, and two newer immunology drugs, Skyrizi and Rinvoq, have more than replaced the lost sales.
The bull case: Skyrizi and Rinvoq are growing fast, and AbbVie keeps adding new conditions they can treat. The company is also buying its way to more growth, including its $10.9 billion deal for Apogee Therapeutics.
The risk: AbbVie carries a heavy debt load from past acquisitions, which limits its room to maneuver if a big bet does not pay off.
Key number: AbbVie has raised its dividend for more than 50 years counting its history as part of Abbott.
Merck (NYSE: MRK)
Why it made the list: Merck owns Keytruda, the best-selling cancer drug in the world and one of the best-selling medicines of any kind. It anchors a deep cancer business that has driven years of growth.
The bull case: Merck is spreading its bets ahead of Keytruda's patent loss, with a version that can be injected under the skin, a large vaccine business, and a fast-rising heart drug called Winrevair.
The risk: Keytruda loses US patent protection in 2028, and replacing that much revenue is the biggest challenge the company faces.
Key number: Keytruda generates roughly $30 billion in annual sales, close to half of Merck's total revenue.
AstraZeneca (NYSE: AZN)
Why it made the list: AstraZeneca has become one of the fastest-growing big drugmakers, led by a deep cancer portfolio. The company trades on the US market as an ADR, a way to own a foreign-listed stock in dollars.
The bull case: AstraZeneca has set a goal of reaching $80 billion in annual revenue by 2030, nearly double its level a few years ago, with new cancer and rare-disease drugs leading the way. Its pipeline is among the deepest in the industry.
The risk: A large share of its growth depends on China and on late-stage trials that still need to deliver, so a setback in either could slow the plan.
Key number: AstraZeneca is targeting $80 billion in annual revenue by 2030, one of the most ambitious growth goals in pharma.
Pfizer (NYSE: PFE)
Why it made the list: Pfizer is rebuilding after its COVID vaccine and treatment sales faded. The stock now pays one of the largest dividends in the market, which pays investors to wait for the turnaround.
The bull case: Newer and acquired products grew 22% in the first quarter, and Pfizer is pushing hard into cancer drugs after its purchase of Seagen. Cost cuts have lifted profit even as older sales slip.
The risk: Pfizer faces its own patent cliff, with blood thinner Eliquis and other drugs losing protection, which raises questions about whether the dividend can keep growing.
Key number: Pfizer's dividend yields close to 7%, among the highest of any large US company.
Bristol Myers Squibb (NYSE: BMY)
Why it made the list: Bristol Myers Squibb trades at one of the lowest valuations among big drugmakers, a reflection of the patent cliff it faces. Its newer drugs are starting to fill the gap.
The bull case: A group of recently launched products, including the schizophrenia drug Cobenfy, is growing quickly. The low valuation and high dividend give investors a margin of safety if those new drugs deliver.
The risk: Older blockbusters Eliquis, Opdivo, and Revlimid all face competition, and the new portfolio has to scale fast enough to offset them.
Key number: Bristol Myers trades at under 10 times forward earnings, a measure called the price-to-earnings ratio that shows how much investors pay for each dollar of expected profit, roughly half the S&P 500's level.
What Is Driving Pharma Stocks Right Now
The sector is shaped by one big problem and one big opportunity. The problem is the patent cliff. Some of the best-selling drugs ever made lose protection over the next few years, and the companies that own them need new products to replace billions in lost sales. The fastest way to do that is to buy a smaller company with an approved drug or a promising pipeline, which is why takeover offers have been landing almost weekly. Our coverage of AbbVie's $10.9 billion deal for Apogee and the broader wave of biotech buyouts shows how aggressive buyers have become.
The opportunity is obesity. Weight-loss drugs have created one of the fastest-growing markets in the history of medicine, and analysts expect it to reach roughly $80 billion in yearly sales by 2030. Eli Lilly leads, and its low-cost weight-loss pill is widening that lead. Rivals are racing to catch up with their own pills and injections. For a wider view of the sector, see our guide to the best healthcare stocks.
Policy is the wild card. Drug pricing rules and the threat of tariffs on imported medicines could squeeze profits, and these companies spend heavily to lobby on both. The effect on any one stock is hard to predict, which is one reason the group trades at a discount to the broader market.
What to watch:
- Obesity competition: New weight-loss pills and trial results from Lilly and its rivals could reshape who leads the fastest-growing market in pharma.
- Keytruda's transition: Merck's progress in launching new drugs and a subcutaneous version of Keytruda will show whether it can offset the 2028 patent loss.
- Drug pricing policy: Decisions on pricing rules and possible tariffs on imported medicines could move the whole sector at once.
Bottom Line
This list is for investors who want exposure to drug companies through large, profitable names rather than speculative bets. Eli Lilly and AstraZeneca offer the most growth, Johnson & Johnson and AbbVie pair growth with decades of rising dividends, and Pfizer and Bristol Myers are cheaper turnaround plays with high yields. Matching the mix to your goals is the sensible way to own the group.
Frequently Asked Questions
What are the best pharmaceutical stocks to buy right now?
Strong large-cap pharmaceutical stocks right now include Eli Lilly, Johnson & Johnson, AbbVie, Merck, AstraZeneca, Pfizer, and Bristol Myers Squibb. Each has at least one blockbuster drug on the market and a pipeline of new treatments in late-stage testing, which is what separates a durable drugmaker from a one-product company.
Are pharmaceutical stocks a good investment?
Pharmaceutical stocks tend to hold up well when the broader market falls because people need medicine in any economy. The trade-off is the patent cliff, since each company eventually loses protection on its top sellers. The best long-term picks are the ones with deep pipelines and growing new drugs, which is why screening for revenue growth and balance sheet strength matters.
What is the difference between pharmaceutical and biotech stocks?
Pharmaceutical companies usually make drugs through traditional chemistry and tend to be large, diversified, and dividend-paying. Biotech companies develop drugs from living systems such as genes, proteins, and cells, and are often younger and faster-growing. The line has blurred as big pharma buys biotechs, but the names on this list are the larger, more diversified drugmakers. For the other side, see our guide to the best biotech stocks.
Which pharmaceutical stock pays the highest dividend?
Among large drugmakers, Pfizer pays one of the highest dividends, with a yield close to 7%. The high payout reflects a low share price as the company works through a patent cliff and rebuilds after its COVID sales faded. A yield that high can signal value or risk, so the key question is whether the company can keep funding it.
What is the patent cliff and why does it matter for pharma stocks?
A patent cliff is the point when a drug loses its patent protection and faces cheaper copies, which can erase most of its sales within a year or two. It matters because medicines worth more than $200 billion in annual sales could lose protection by 2030. Companies that line up new drugs ahead of those losses keep growing, while those that do not can see revenue shrink.
